Posted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 million to $2.05 million; recommendations encourage drug makers to set prices toward lower end of this range to facilitate access and affordability across all insurance systems.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of exagamglogene autotemcel (Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (bluebird bio) for sickle cell disease.
